GNTA
vs
S&P 500
GNTA
S&P 500
Over the past 12 months, GNTA has underperformed S&P 500, delivering a return of -77% compared to the S&P 500's +14% growth.
Stocks Performance
GNTA vs S&P 500
Performance Gap
GNTA vs S&P 500
Performance By Year
GNTA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genenta Science SPA
Glance View
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.